Influence of DOAC Remove on Coagulation Assays During Thrombophilia Testing in Patients Treated with Rivaroxaban or Dabigatran
Apstrakt
Background: Direct oral anticoagulants (DOAC) are increasingly being used as an alternative to warfarin in the treatment of venous thromboembolism. DOAC administration has a significant impact on coagulation assays. This is especially important during thrombophilia testing.
Aims: To evaluate the effect of DOAC Remove on coagulation assays during thrombophilia testing in patients treated with DOAC.
Methods: We have used samples from 20 patients treated with DOAC. Two samples of venous blood on sodium citrate were taken for each patient. One was prepared by standard method for coagulation assays, while, the second one was prepared using DOAC Remove. According to the instruction the samples were mixed gently for 5 minutes with DOAC Remove tablet, and then centrifuged 2 minutes on 2000g. The supernatant after centrifugation is used to the coagulation assays. So prepared samples were used in the thrombophilia testing.
Results: Before DOAC Remove in 10 patients treated with Rivaroxa...ban average APTT of 31.5s; PT 104%; LA1 51.7s; LA2 40.3s; LA- R 1.28, AT 104%, PC 104%, PS 87% and APC-R 4.1 were obtained. In Dabigatran patients APTT 40.5s, PT 104%; LA1 73.7s; LA2 53.7s; LA-R 1.37, AT 103% PC 98% and PS 82% were obtained. In relation to the APC-R test, in half of the investigated patients no result for APC-R was obtained, while, for the rest, average APC-R of 6.5 were obtained. After DOAC Remove in Rivaroxaban patients APTT 29.7s; PT 110%; LA1 37.3s; LA2 33.8s; LA- R 1.12, AT 96%, PC 102%, PS 88% and APCR 4.2 were recorded. In Dabigatran patients APTT 28.1s, PT 117%; LA 39.1s; LA2 33.8s; LA-R 1.15, AT 104%, PC 97.5%, PS 84.5% and APC-R 6.5 were recorded.
Conclusions: DOAC was practically inactivated after the addition of the DOAC Remove, which made it possible to perform analyzes for the LA and APC-R testing freely and obtain relevant results.
Izvor:
ISTH 2020 Congress, 2020, PB0633-Izdavač:
- John Wiley & Sons
Napomena:
- ISTH 2020 Congress; July 12-14, 2020. Virtual Congress.
URI
https://imagine.imgge.bg.ac.rs/handle/123456789/1636https://abstracts.isth.org/abstract/influence-of-doac-remove-on-coagulation-assays-during-thrombophilia-testing-in-patients-treated-with-rivaroxaban-or-dabigatran/
Institucija/grupa
Institut za molekularnu genetiku i genetičko inženjerstvoTY - CONF AU - Kovač, M. AU - Basarić, D. AU - Tomić, Branko AU - Backović, D. AU - Lalić Cosić, S. PY - 2020 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1636 UR - https://abstracts.isth.org/abstract/influence-of-doac-remove-on-coagulation-assays-during-thrombophilia-testing-in-patients-treated-with-rivaroxaban-or-dabigatran/ AB - Background: Direct oral anticoagulants (DOAC) are increasingly being used as an alternative to warfarin in the treatment of venous thromboembolism. DOAC administration has a significant impact on coagulation assays. This is especially important during thrombophilia testing. Aims: To evaluate the effect of DOAC Remove on coagulation assays during thrombophilia testing in patients treated with DOAC. Methods: We have used samples from 20 patients treated with DOAC. Two samples of venous blood on sodium citrate were taken for each patient. One was prepared by standard method for coagulation assays, while, the second one was prepared using DOAC Remove. According to the instruction the samples were mixed gently for 5 minutes with DOAC Remove tablet, and then centrifuged 2 minutes on 2000g. The supernatant after centrifugation is used to the coagulation assays. So prepared samples were used in the thrombophilia testing. Results: Before DOAC Remove in 10 patients treated with Rivaroxaban average APTT of 31.5s; PT 104%; LA1 51.7s; LA2 40.3s; LA- R 1.28, AT 104%, PC 104%, PS 87% and APC-R 4.1 were obtained. In Dabigatran patients APTT 40.5s, PT 104%; LA1 73.7s; LA2 53.7s; LA-R 1.37, AT 103% PC 98% and PS 82% were obtained. In relation to the APC-R test, in half of the investigated patients no result for APC-R was obtained, while, for the rest, average APC-R of 6.5 were obtained. After DOAC Remove in Rivaroxaban patients APTT 29.7s; PT 110%; LA1 37.3s; LA2 33.8s; LA- R 1.12, AT 96%, PC 102%, PS 88% and APCR 4.2 were recorded. In Dabigatran patients APTT 28.1s, PT 117%; LA 39.1s; LA2 33.8s; LA-R 1.15, AT 104%, PC 97.5%, PS 84.5% and APC-R 6.5 were recorded. Conclusions: DOAC was practically inactivated after the addition of the DOAC Remove, which made it possible to perform analyzes for the LA and APC-R testing freely and obtain relevant results. PB - John Wiley & Sons C3 - ISTH 2020 Congress T1 - Influence of DOAC Remove on Coagulation Assays During Thrombophilia Testing in Patients Treated with Rivaroxaban or Dabigatran SP - PB0633 UR - https://hdl.handle.net/21.15107/rcub_imagine_1636 ER -
@conference{ author = "Kovač, M. and Basarić, D. and Tomić, Branko and Backović, D. and Lalić Cosić, S.", year = "2020", abstract = "Background: Direct oral anticoagulants (DOAC) are increasingly being used as an alternative to warfarin in the treatment of venous thromboembolism. DOAC administration has a significant impact on coagulation assays. This is especially important during thrombophilia testing. Aims: To evaluate the effect of DOAC Remove on coagulation assays during thrombophilia testing in patients treated with DOAC. Methods: We have used samples from 20 patients treated with DOAC. Two samples of venous blood on sodium citrate were taken for each patient. One was prepared by standard method for coagulation assays, while, the second one was prepared using DOAC Remove. According to the instruction the samples were mixed gently for 5 minutes with DOAC Remove tablet, and then centrifuged 2 minutes on 2000g. The supernatant after centrifugation is used to the coagulation assays. So prepared samples were used in the thrombophilia testing. Results: Before DOAC Remove in 10 patients treated with Rivaroxaban average APTT of 31.5s; PT 104%; LA1 51.7s; LA2 40.3s; LA- R 1.28, AT 104%, PC 104%, PS 87% and APC-R 4.1 were obtained. In Dabigatran patients APTT 40.5s, PT 104%; LA1 73.7s; LA2 53.7s; LA-R 1.37, AT 103% PC 98% and PS 82% were obtained. In relation to the APC-R test, in half of the investigated patients no result for APC-R was obtained, while, for the rest, average APC-R of 6.5 were obtained. After DOAC Remove in Rivaroxaban patients APTT 29.7s; PT 110%; LA1 37.3s; LA2 33.8s; LA- R 1.12, AT 96%, PC 102%, PS 88% and APCR 4.2 were recorded. In Dabigatran patients APTT 28.1s, PT 117%; LA 39.1s; LA2 33.8s; LA-R 1.15, AT 104%, PC 97.5%, PS 84.5% and APC-R 6.5 were recorded. Conclusions: DOAC was practically inactivated after the addition of the DOAC Remove, which made it possible to perform analyzes for the LA and APC-R testing freely and obtain relevant results.", publisher = "John Wiley & Sons", journal = "ISTH 2020 Congress", title = "Influence of DOAC Remove on Coagulation Assays During Thrombophilia Testing in Patients Treated with Rivaroxaban or Dabigatran", pages = "PB0633", url = "https://hdl.handle.net/21.15107/rcub_imagine_1636" }
Kovač, M., Basarić, D., Tomić, B., Backović, D.,& Lalić Cosić, S.. (2020). Influence of DOAC Remove on Coagulation Assays During Thrombophilia Testing in Patients Treated with Rivaroxaban or Dabigatran. in ISTH 2020 Congress John Wiley & Sons., PB0633. https://hdl.handle.net/21.15107/rcub_imagine_1636
Kovač M, Basarić D, Tomić B, Backović D, Lalić Cosić S. Influence of DOAC Remove on Coagulation Assays During Thrombophilia Testing in Patients Treated with Rivaroxaban or Dabigatran. in ISTH 2020 Congress. 2020;:PB0633. https://hdl.handle.net/21.15107/rcub_imagine_1636 .
Kovač, M., Basarić, D., Tomić, Branko, Backović, D., Lalić Cosić, S., "Influence of DOAC Remove on Coagulation Assays During Thrombophilia Testing in Patients Treated with Rivaroxaban or Dabigatran" in ISTH 2020 Congress (2020):PB0633, https://hdl.handle.net/21.15107/rcub_imagine_1636 .